Browse by author
Lookup NU author(s): Professor Catharien Hilkens
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The central effector cells in the pathogenesis of atopic allergic diseases are type 2 T helper (Th2) cells, which display an aberrant cytokine profile dominated by type 2 cytokines. Initial reports from mouse studies indicated that established and committed Th2 cells are stable and unsusceptible to modulation. However, there is a growing awareness that in humans, established effector Th2 cells are more flexible and can be reverted to predominant Th1 phenotypes. In fact, the Th1-driving cytokine interleukin (IL)-12 is the crucial factor in this respect. IL-12 is mainly produced by dendritic cells (DC), which can be primed for high or low IL-12 production, depending on inflammatory and/or microbial signals they encounter during their residence in the peripheral tissues. Accordingly, both the regulation of and the priming for IL-12 production in DC form ideal targets for therapeutic intervention. The development of new therapies for atopic allergy now focuses on local IL-12-promoting substances to target both the development of new Th2 cells and the persistent population of established allergen-specific Th2 cells.
Author(s): Smits HH, Hilkens CM, Kalinski P, Kapsenberg ML, Wierenga EA
Publication type: Article
Publication status: Published
Journal: International Archives of Allergy and Immunology
Print publication date: 01/10/2001
ISSN (print): 1018-2438
ISSN (electronic): 1423-0097
Publisher: S. Karger AG
Altmetrics provided by Altmetric